Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0BJAJD |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | h7G3EC |
|||||
| Synonyms |
h7G3EC
Click to Show/Hide
|
|||||
| Antigen Name | Interleukin-3 receptor subunit alpha (IL3RA) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
SGN-CD123A [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligibility requires CD123-positive AML patients with 1-3 prior regimens (high-risk cases may qualify after 1 regimen), adequate organ function and ECOG 0-1, excluding those with CNS involvement, promyelocytic leukemia, significant pulmonary dysfunction, recent transplants, or recent antileukemia/experimental treatments within 4 weeks (hydroxyurea/6-MP allowed).
Click to Show/Hide
|
||||
| Administration Dosage |
Intravenous infusion in 3-week cycles
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02848248 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1 Study of SGN-CD123A in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
||||
| Primary Endpoint |
The primary safety endpoints assess adverse event profiles (type/incidence/severity/seriousness/relatedness) and lab abnormalities during treatment and 1-month post-treatment, along with dose-limiting toxicity incidence during the initial 3-week cycle.
|
||||
| Other Endpoint |
Secondary objectives include pharmacokinetic analysis (SGN-CD123A blood concentrations), immunogenicity (antitherapeutic antibodies), and efficacy measures (remission rate, complete remission duration, leukemia-free survival, and overall survival) monitored for approximately 1 year in relapsed/refractory AML patients.
|
||||